BioPharmSignal logoBioPharmSignal

Biotech News

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma (ATYR)aTyr PharmaCompany update

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation

Open original release

Related news

ATYRaTyr Pharma2026-05-15 12:00 EST

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

ATYRaTyr Pharma2026-05-13 20:01 EST

aTyr Pharma to Participate in Upcoming Investor Conferences

ZURAZura Bio2026-05-14 11:30 EST

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

AVTXAvalo Therapeutics2026-05-22 20:01 EST

Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

aTyr Pharma

aTyr Pharma is a biotechnology company focused on extracellular biology and inflammatory disease. Its story is centered on using novel biology to address serious immune-mediated conditions.

Recent company news

ATYRaTyr Pharma2026-05-15 12:00 EST

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

ATYRaTyr Pharma2026-05-13 20:01 EST

aTyr Pharma to Participate in Upcoming Investor Conferences

ATYRaTyr Pharma2026-05-11 20:01 EST

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

ATYRaTyr Pharma2026-03-05 21:01 EST

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

ATYRaTyr Pharma2026-02-20 21:01 EST

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
0.49 USD
Market cap
50.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States